Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SET-HAPLO in Refractory AML
NCT03035422Phase 2Completed
- Start
- Jan 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thiotepa, cyclophosphamide, etoposide in acute myeloid leukemia (AML). Started Jan 2018; status: completed.
02
Drugs
thiotepacyclophosphamideetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03035422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035422.